Die Weihnachtschance ??? - 500 Beiträge pro Seite

[URANI]

Folgende Aktie könnte die Weihnachtschance werden oder natürlich auch ein TOTALVERLUST. Gestern wurden in Kanada 4,5 Mio. Shares umgesetzt und das Volumen in den letzten Tagen stieg stark an.

http://www.nuvoresearch.com



WKN: A0HHKB
Symbol: DLA
ISIN: CA67072X1096







Nuvo Research für Spekulative Datum: 12.12.06 Uhrzeit: 10:16

Endingen (aktiencheck.de AG) - Die Experten von "Global Biotech Investing" halten die Aktie von Nuvo Research (ISIN CA67072X1096/ WKN A0HHKB) für den spekulativ veranlagten Anleger für interessant.
Bei Nuvo Research sorge derzeit das Osteoarthritis-Mittel Pennsaid für Fantasie. Das Präparat sei bereits in einigen europäischen Ländern und in Kanada verfügbar und sei 2002 von der amerikanischen Gesundheitsbehörde abgelehnt worden. Die FDA habe sich aber nun dazu verpflichtet, Pennsaid bis spätestens 28. Dezember erneut zu prüfen. Unterstelle man, dass zwischen den Jahren nicht mehr viel los sei, könnte eine Entscheidung bereits Ende kommender Woche gefällt werden.
Pennsaid habe in Phase III-Testreihen mit 775 Patienten alle klinischen Endziele erreicht und seine Wirksamkeit gegenüber einer Placebo-Vergleichsgruppe unter Beweis gestellt. Vor diesem Hintergrund sähen die Experten sehr gute Chancen für eine Zulassung von Pennsaid. Mit dem Mittel würde Nuvo Research einen 6,5 Mrd. USD-Markt betreten. Komme es zur Zulassung durch die FDA, dürfte der Titel vor einer Neubewertung stehen.
Spekulativ orientierte sollten in den kommenden beiden Wochen deshalb unbedingt eine Position der Nuvo Research-Aktie im Depot haben, so die Experten von "Global Biotech Investing". (Ausgabe 23 vom 11.12.2006)
(12.12.2006/ac/a/a)

[URANI]

Pennsaid® (1.5% w/w diclofenac sodium solution)

Pennsaid®, the first medication based on the company's patented transcellular technology, is used to treat osteoarthritis pain and stiffness. The drug combines a proprietary carrier with diclofenac sodium, a leading nonsteroidal anti-inflammatory drug (NSAID), and delivers active ingredient through the skin directly to the pain site. After many clinical studies, Pennsaid® lotion has not been linked to the problems often found with conventional NSAID treatment.

When used regularly, NSAID pills can cause numerous side effects. The most severe are ulcers and gastrointestinal bleeding, but they can also include blood pressure increases, dizziness, headache, depression and delayed stomach emptying.

With topically applied Pennsaid®, the most common adverse reaction has been mild dryness or irritation at the application site. A recent equivalence study has also shown that Pennsaid® works as well as the maximum daily dose of oral diclofenac, without provoking serious side effects..

Pennsaid® is currently available in Canada, the United Kingdom, Italy, Greece, Portugal and the Caribbean. The Company has recently completed Phase III Clinical Trials for efficacy/safety and anticipate long-term safety trial results in February 2006. Nuvo expects to file an amended New Drug Application (NDA) for Pennsaid® with the U.S. Food and Drug Administration (FDA) in mid 2006.

[GERILLAS]

Langfristig orienterte Anleger sollten sich OEGY A0JNEA unbedingt anschauen

Charttechnisch sollte der Ausbruch nach oben so langsam fällig sein

Der Abwärtstrend wird immer steiler

Möglich das wir noch 10% abgeben dafür sind die Chancen nach oben 10 mal höher

[Plusquamperfekt]

Eine leckere Intradaychance gibts hier

Thread: SUDA LTD ehemals Eastland Medical

[buxte]

Antwort auf Beitrag Nr.: 26.304.265 von URANI am 19.12.06 13:57:31

habe die auch schon im Focus.

buxte

[URANI]

Antwort auf Beitrag Nr.: 26.310.195 von buxte am 19.12.06 17:38:29

Das ist sehr gut..............

[URANI]

In Kanada wird wie wild spekuliert. Im falle einer FDA-Zulassung für Amerika geht man mit Kursen über 5 $ aus bzw. kreisen erste Gerüchte das im erfolgreichen falle einer Zulassung evt. SmithGlaxoKline interesse an Nuvo haben könnte.

Naja, erstmal fiebern wir wohl den 28 Dezember entgegen und dann sehen wir weiter.............

[URANI]

http://quotes.barchart.com/texpert.asp?sym=nri.to

[URANI]

Composite Indicator
Trend Spotter TM Buy
Short Term Indicators
7 Day Average Directional Indicator Buy
10 - 8 Day Moving Average Hilo Channel Buy 20 Day Moving Average vs Price Buy
20 - 50 Day MACD Oscillator Buy
20 Day Bollinger Bands Buy

Short Term Indicators Average:
100% - Buy 20-Day Average Volume - 458

Medium Term Indicators
40 Day Commodity Channel Index Buy
50 Day Moving Average vs Price Buy
20 - 100 Day MACD Oscillator Buy
50 Day Parabolic Time/Price Buy

Medium Term Indicators Average:
100% - Buy 50-Day Average Volume - 428

Long Term Indicators
60 Day Commodity Channel Index Buy
100 Day Moving Average vs Price Buy
50 - 100 Day MACD Oscillator Sell
Long Term Indicators Average: 33% - Buy
100-Day Average Volume - 454

Overall Average: 88% - Buy

[URANI]

Mr. Bennett urges investors to keep an eye on Nuvo Research Inc., which is scheduled to receive an FDA marketing decision before the end of the year for its flagship Pennsaid lotion for osteoarthritis. Also waiting in the wings for FDA decisions in 2007 are Labopharm Inc. and Neurochem Inc.

[URANI]

Time Ex Price Change Volume Buyer Seller Markers

10:22:05 T 0.61 +0.03 100 80 National Bank 80 National Bank E

10:22:05 T 0.61 +0.03 65,000 80 National Bank 80 National Bank K

10:21:34 T 0.61 +0.03 200 79 CIBC 84 Ind Trading E

10:21:34 T 0.61 +0.03 1,000 79 CIBC 80 National Bank K

10:21:34 T 0.61 +0.03 500 79 CIBC 84 Ind Trading K

10:16:58 T 0.61 +0.03 400 85 Scotia 84 Ind Trading E

10:16:58 T 0.61 +0.03 500 85 Scotia 80 National Bank K

10:16:32 T 0.61 +0.03 1,500 85 Scotia 80 National Bank K

10:16:32 T 0.61 +0.03 500 85 Scotia 84 Ind Trading K

10:10:26 T 0.61 +0.03 2,000 88 E-TRADE 80 National Bank K

[URANI]

RT 0,67 CAD

[URANI]

[URANI]

[URANI]

Rt 0,77 CAD
Volumen: 2,8 Mio.

[URANI]

Time Ex Price Change Volume Buyer Seller Markers
15:35:35 T 0.65 +0.02 2,000 7 TD Sec 80 National Bank K

15:35:35 T 0.65 +0.02 1,000 7 TD Sec 84 Ind Trading K

15:35:35 T 0.65 +0.02 3,000 2 RBC 80 National Bank K

15:35:35 T 0.65 +0.02 2,000 2 RBC 84 Ind Trading K

15:35:28 T 0.65 +0.02 500 1 Anonymous 84 Ind Trading K

15:35:20 T 0.65 +0.02 49,500 1 Anonymous 79 CIBC K

15:35:20 T 0.65 +0.02 500 80 National Bank 79 CIBC K

15:35:10 T 0.65 +0.02 24,500 80 National Bank 79 CIBC K

15:35:10 T 0.65 +0.02 25,000 1 Anonymous 79 CIBC K

15:35:10 T 0.65 +0.02 4,500 7 TD Sec 79 CIBC K

[URANI]

Nuvo licenses Canadian Pennsaid Plus rights to Squire


2006-12-22 13:50 ET - News Release

Mr. Jonathan Ross Goodman reports

NUVO LICENSES CANADIAN PENNSAID PLUS RIGHTS TO SUBSIDIARY OF PALADIN

Squire Pharmaceuticals Inc., a subsidiary of Paladin Labs Inc., has exercised its right to enter into a licence with Nuvo Research Inc. to market and sell Pennsaid Plus in Canada. Squire obtained an option to license Pennsaid Plus as part of a previously announced transaction (reported in Stockwatch on Jan. 17, 2006), when Nuvo sold a portion of its Canadian Pennsaid revenue stream to Squire. Pennsaid Plus is a follow-on product to Nuvo's Pennsaid, a topical NSAID for the treatment of osteoarthritis, and is designed to provide users with the efficacy of existing Pennsaid, but with less frequent dosing and increased ease of application. Patent applications for Pennsaid have been filed and a pivotal phase III trial for the product is expected to begin in 2007. Squire currently markets and sells Pennsaid in Canada under licence from Nuvo.

The Pennsaid Plus licence includes an upfront payment to Nuvo and royalties on future Canadian sales of Pennsaid Plus. As part of the licensing arrangement, Squire has also invested $500,000 in Nuvo through a three-year debenture convertible into Nuvo shares at a conversion price of 60 cents, which is based on the prior 10-day average weighted closing price of Nuvo common shares.

"We are pleased to expand our relationship with Paladin, a firm with the proven ability to successfully build leading brands in Canada," said John London, Nuvo's vice-chairman. "This transaction solidifies our long-term Canadian strategy for Pennsaid and Pennsaid Plus and affirms Paladin's commitment to expansion of the Canadian market for our lead products."

"Pennsaid sales in Canada grew 22 per cent in 2006 to $10.5-million. This growth is driven by clinical evidence that indicates that Pennsaid is as effective as oral diclofenac, considered the 'gold standard' treatment for osteoarthritis, but with significantly fewer adverse events," said Jonathan Ross Goodman, president and chief executive officer of Paladin. "We believe that Pennsaid Plus, with fewer applications required per day coupled with a more convenient formulation, will be well received by the four million Canadians living with osteoarthritis."

We seek Safe Harbor.

[URANI]

Globe says U.S. FDA puts Nuvo pain lotion in motion


2007-01-02 05:56 ET - In the News

[SharpRatio]

Antwort auf Beitrag Nr.: 26.304.265 von URANI am 19.12.06 13:57:31

Daraus wird eine Januar-Chance!

[URANI]

Antwort auf Beitrag Nr.: 26.907.837 von SharpRatio am 14.01.07 13:30:57

Stimmt... aber was noch nicht ist kann ja noch werden....

[SharpRatio]

Antwort auf Beitrag Nr.: 26.909.354 von URANI am 14.01.07 14:25:37

Absolut korrekt!

[SharpRatio]

Antwort auf Beitrag Nr.: 26.304.265 von URANI am 19.12.06 13:57:31

Wird z. B. Johnson&Johnson vermeldet, dann sehen wir leicht den Dollar. Ich bin zuversichtlich, zumal unter "Börsengeflüster" bei Börse Online Gleiches verlautbart wurde. Aber nur Geflüster halt.